Emergency UsageBharat has spent about $60 million to $70 million so far developing Covid vaccines, and early trial data suggest Covaxin, an inactivated candidate that uses a dead version of the virus, has efficacy rates of at least 60%, which Ella said was a “conservative" projection.That may improve in the final human study, she said.
The trial has recruited half of its 26,000 volunteers, and going into 2021 Ella expects licensing to allow inoculations for public use by May or June.The lack of phase III trial data didn’t stop Bharat from applying for emergency use authorization this month, though the company and Serum Institute -- which has submitted final phase numbers -- have been asked by Indian regulators to provide additional figures.